Breast surgical oncologist Alexa Glencer has joined UC Davis Comprehensive Cancer Center, bringing a focus on treating high-risk breast cancer patients and enrolling them in clinical trials. She specializes in caring for patients with inflammatory breast cancer and those with ductal carcinoma in situ (DCIS). Glencer also cares for patients in the I-SPY 2 trial that rapidly screens multiple drugs and matches them to the specific breast cancer subtypes where they can be most effective.
Glencer is also a dedicated researcher. She has studied how the immune system interacts with DCIS and explored new mRNA-based treatments. She is working to open a new clinical trial intended to compare treatments for patients with DCIS. She’ll distinguish which patients benefit from surgery and which patients benefit from novel and less toxic endocrine therapy without surgical intervention. She also leads the UC Davis site for the WISDOM trial, which is testing a personalized approach to breast cancer screening using genetic and clinical risk factors.
“We are thrilled to have Dr. Glencer join our team as part of our intentional efforts to increase timely access to unparalleled breast cancer treatments for our communities,” said UC Davis Comprehensive Cancer Center Physician-in-Chief David Tom Cooke. “Her clinical expertise and research leadership will help us continue to provide the most advanced, compassionate care to our patients while shaping the future of breast cancer treatment.”
Glencer earned her undergraduate degree from Princeton University and her medical degree from UCSF School of Medicine. She completed her surgical training at UCSF and a breast surgical oncology fellowship at MD Anderson Cancer Center.
